CELLECTIS S.A. - AMERICAN DEPOSITARY SHARES Depository Receipt · US15117K1034 · CLLS · A14QZE (XNMS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of CELLECTIS S.A. - AMERICAN DEPOSITARY SHARES

No Price

01.05.2026 20:00

Current Prices from CELLECTIS S.A. - AMERICAN DEPOSITARY SHARES

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	CLLS	USD	01.05.2026 20:00	3,95 USD	0,05 USD +1,28 %
IEX	CLLS	USD	01.05.2026 19:58	3,96 USD	0,06 USD +1,54 %
Düsseldorf	CANSAD34.DUSB	EUR	30.04.2026 06:12	3,12 EUR	-
Quotrix	CANSAD34.DUSD	EUR	30.04.2026 05:27	3,20 EUR	-

Invested Funds

The following funds have invested in CELLECTIS S.A. - AMERICAN DEPOSITARY SHARES:

Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	Vol. in million 9,41	Percentage (%) 0,02 %

Company Profile for CELLECTIS S.A. - AMERICAN DEPOSITARY SHARES Depository Receipt

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.